Navidea Biopharmaceuticals falls as Aegis cuts target

|About: Navidea Biopharmaceuticals (NAVB)|By:, SA News Editor

Shares of Navidea Biopharmaceuticals (NAVB -4.3%) trade lower out of the gate.

Behind the move looks to be Aegis, where, according to market chatter, analysts have cut their price target.

Reminder: Q3 Lymphoseek sales were $144K.

In other company news, NAVB says it will collaborate with the University of San Francisco "on a clinical study to evaluate, for the first time, the use and performance of technetiumlabeled tilmanocept in patients with Kaposi Sarcoma." (PR)